Ares Financial Consulting
DFTX icon

Ares Financial Consulting’s Definium Therapeutics DFTX Stock Holding History

Ares Financial Consulting’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-8
Closed -$376 – 1110
2026
Q2 		$376 Buy
+8
New +$198 ﹤0.01% 1099

Other funds holding DFTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Ares Financial Consulting's DFTX Position: Q3 2026 in Review

Ares Financial Consulting sold out of Definium Therapeutics (DFTX) in Q3 2026, closing a stake of 8 shares — an estimated $376 sold.

Ares Financial Consulting first reported a position in DFTX in Q2 2026 and held it in 1 quarter. The position peaked at $376 in Q2 2026. 237 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Ares Financial Consulting reported no remaining Definium Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 8 Definium Therapeutics shares in Q3 2026, an estimated $376.
  • Ares Financial Consulting first reported a position in Definium Therapeutics in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Definium Therapeutics position peaked at $376 in Q2 2026.
  • 237 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.